

# Ziva Cooper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1437643/publications.pdf>

Version: 2024-02-01

72  
papers

3,051  
citations

147801

31  
h-index

168389

53  
g-index

74  
all docs

74  
docs citations

74  
times ranked

2769  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. <i>Neuropsychopharmacology</i> , 2018, 43, 34-51.	5.4	223
2	Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. <i>Current Psychiatry Reports</i> , 2016, 18, 52.	4.5	200
3	Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. <i>Neuropsychopharmacology</i> , 2016, 41, 1974-1982.	5.4	160
4	Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. <i>Drug and Alcohol Dependence</i> , 2009, 103, 107-113.	3.2	155
5	Investigation of sex-dependent effects of cannabis in daily cannabis smokers. <i>Drug and Alcohol Dependence</i> , 2014, 136, 85-91.	3.2	136
6	Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. <i>Addiction Biology</i> , 2008, 13, 188-195.	2.6	124
7	Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse. <i>Neuropsychopharmacology</i> , 2013, 38, 1557-1565.	5.4	112
8	Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. <i>Neuropsychopharmacology</i> , 2018, 43, 2046-2055.	5.4	110
9	Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. <i>International Review of Psychiatry</i> , 2009, 21, 104-112.	2.8	98
10	Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. <i>Addiction</i> , 2010, 105, 709-718.	3.3	94
11	Predictors of Marijuana Relapse in the Human Laboratory: Robust Impact of Tobacco Cigarette Smoking Status. <i>Biological Psychiatry</i> , 2013, 73, 242-248.	1.3	86
12	The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. <i>Addiction Biology</i> , 2016, 21, 895-903.	2.6	85
13	Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. <i>Psychopharmacology</i> , 2010, 211, 233-244.	3.1	71
14	Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers. <i>Neuropsychopharmacology</i> , 2013, 38, 1984-1992.	5.4	71
15	Sex-dependent effects of cannabis-induced analgesia. <i>Drug and Alcohol Dependence</i> , 2016, 167, 112-120.	3.2	67
16	Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. <i>Addiction Biology</i> , 2013, 18, 872-881.	2.6	61
17	Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis. <i>PLoS Medicine</i> , 2019, 16, e1002967.	8.4	56
18	Paradoxical Effects of Chronic Morphine Treatment on the Temperature and Pituitary-Adrenal Responses to Acute Restraint Stress: A Chronic Stress Paradigm. <i>Journal of Neuroendocrinology</i> , 2001, 13, 862-874.	2.6	55

#	ARTICLE	IF	CITATIONS
19	Morphine Deprivation Increases Self-Administration of the Fast- and Short-Acting $\mu$ -Opioid Receptor Agonist Remifentanyl in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 920-929.	2.5	55
20	Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. <i>Neuropsychopharmacology</i> , 2015, 40, 2489-2498.	5.4	55
21	Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. <i>Current Addiction Reports</i> , 2014, 1, 137-143.	3.4	53
22	Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. <i>Psychopharmacology</i> , 2010, 211, 141-148.	3.1	51
23	A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. <i>Addiction Biology</i> , 2013, 18, 993-1002.	2.6	50
24	Rapid and Robust Protection against Cocaine-Induced Lethality in Rats by the Bacterial Cocaine Esterase. <i>Molecular Pharmacology</i> , 2006, 70, 1885-1891.	2.3	49
25	Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers. <i>Neuropsychopharmacology</i> , 2013, 38, 2427-2438.	5.4	49
26	Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers. <i>Psychopharmacology</i> , 2010, 208, 45-55.	3.1	47
27	Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. <i>Pain</i> , 2013, 154, 1442-1448.	4.2	46
28	Marijuana's dose-dependent effects in daily marijuana smokers.. <i>Experimental and Clinical Psychopharmacology</i> , 2013, 21, 287-293.	1.8	44
29	Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 169-178.	4.1	42
30	Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. <i>Psychopharmacology</i> , 2016, 233, 2469-2478.	3.1	42
31	Cocaine Esterase: Interactions with Cocaine and Immune Responses in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 926-933.	2.5	41
32	A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 347-355.	2.4	32
33	Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 199, 173059.	2.9	28
34	Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. <i>Psychopharmacology</i> , 2010, 212, 369-378.	3.1	27
35	Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. <i>International Journal of Clinical Practice</i> , 2020, 75, e13871.	1.7	26
36	Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. <i>Behavioural Pharmacology</i> , 2013, 24, 504-516.	1.7	25

#	ARTICLE	IF	CITATIONS
37	A Bacterial Cocaine Esterase Protects Against Cocaine-Induced Epileptogenic Activity and Lethality. <i>Annals of Emergency Medicine</i> , 2009, 54, 409-420.	0.6	23
38	Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. <i>Drug and Alcohol Dependence</i> , 2010, 106, 219-229.	3.2	23
39	Challenges for Clinical Cannabis and Cannabinoid Research in the United States. <i>Journal of the National Cancer Institute Monographs</i> , 2021, 2021, 114-122.	2.1	21
40	Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers. <i>Behavioural Pharmacology</i> , 2012, 23, 271-279.	1.7	20
41	Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. <i>Addiction Biology</i> , 2019, 24, 707-716.	2.6	20
42	Effects of menstrual cycle phase on cocaine self-administration in rhesus macaques. <i>Hormones and Behavior</i> , 2013, 63, 105-113.	2.1	17
43	Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. <i>Addiction Biology</i> , 2019, 24, 765-776.	2.6	16
44	Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 706-716.	2.9	16
45	Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers. <i>Drug and Alcohol Dependence</i> , 2017, 178, 340-347.	3.2	15
46	A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 535-547.	2.1	13
47	Drugs of Misuse: Focus on Vascular Dysfunction. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1364-1377.	1.7	12
48	Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 580-595.	2.1	11
49	Cannabis legalization: progress in harm reduction approaches for substance use and misuse. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 707-712.	2.1	11
50	Changes in medical and non-medical cannabis use among United States adults before and during the COVID-19 pandemic. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 321-327.	2.1	11
51	Cannabis and the Opioid Crisis. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 108-116.	2.9	10
52	5HT <sub>2C</sub> agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers. <i>Addiction Biology</i> , 2021, 26, e12993.	2.6	9
53	A Guide to the National Academy of Science Report on Cannabis: An Exclusive Discussion with Panel Members. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 155-159.	2.9	8
54	The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 155-165.	2.9	8

#	ARTICLE	IF	CITATIONS
55	Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. <i>Neuropharmacology</i> , 2018, 134, 92-100.	4.1	7
56	Social motivational processing and interpersonal function in aging cocaine smokers. <i>Addiction Biology</i> , 2019, 24, 1044-1055.	2.6	7
57	Sex-dependent effects of alcohol administration on the urge to use cannabis.. <i>Experimental and Clinical Psychopharmacology</i> , 2021, 29, 689-695.	1.8	7
58	Selective Changes in Medical Cannabis Use Early in the COVID-19 Pandemic: Findings from a Web-Based Sample of Adults in the United States. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 174-183.	2.9	7
59	Cognitive function in aging cocaine smokers. <i>Journal of Psychopharmacology</i> , 2019, 33, 801-810.	4.0	6
60	Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers. <i>Behavioural Pharmacology</i> , 2011, 22, 354-361.	1.7	5
61	Patterns of Use and Self-reported Effectiveness of Cannabis for Hyperemesis Gravidarum. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 517-527.	1.8	5
62	Impact of inpatient research participation on subsequent heroin use patterns: implications for ethics and public health. <i>Addiction</i> , 2012, 107, 642-649.	3.3	4
63	Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers. <i>Addiction Biology</i> , 2022, 27, .	2.6	4
64	Cannabis and Cannabinoid Intoxication and Toxicity. , 2019, , 103-111.		3
65	Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications. <i>Alcohol and Alcoholism</i> , 2020, 55, 416-423.	1.6	2
66	Motivational interviewing to treat substance use disorders in the emergency department: A scoping review. <i>American Journal of Emergency Medicine</i> , 2021, 51, 414-414.	1.6	2
67	Necessity of addressing motivations for cannabis use to guide research. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 547-550.	2.1	1
68	Changes in secondary substance use after the onset of the COVID-19 pandemic among people who use cannabis: Findings from a web-based sample of adults in the United States.. <i>Experimental and Clinical Psychopharmacology</i> , 2023, 31, 482-490.	1.8	1
69	Medications for Treatment of Marijuana Dependence. , 2013, , 397-406.		0
70	F259. Social Motivational Processing and Interpersonal Function in Aging Cocaine Smokers. <i>Biological Psychiatry</i> , 2018, 83, S339-S340.	1.3	0
71	2.10 CANNABIS AND OTHER SUBSTANCE USE, COMORBID PSYCHIATRIC DISORDERS, AND CHILDHOOD ADVERSITY IN AN OUTPATIENT CHILD AND ADOLESCENT PSYCHIATRY CLINIC. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, S174.	0.5	0
72	Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates.. <i>Experimental and Clinical Psychopharmacology</i> , 2021, 29, 137-146.	1.8	0